Premium
A double‐blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis
Author(s) -
Muhammad Jahangir,
Irshad Hussain,
Mumtaz Hasan,
Tahir Saeed Haroon
Publication year - 1998
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1998.02465.x
Subject(s) - terbinafine , tinea capitis , itraconazole , medicine , dermatology , discontinuation , adverse effect , randomized controlled trial , double blind , antifungal , placebo , pathology , alternative medicine
In this randomized, double‐blind study, the efficacy and safety of oral itraconazole ( n = 28) and terbinafine ( n = 27), each given for 2 weeks, was compared in patients with tinea capitis. Trichophyton violaceum was the major pathogen in both groups (82.1% and 88.9%, respectively). The final evaluation at week 12 showed a cure rate of 85.7% and 77.8%, respectively ( P > 0.05). Adverse events noted were mild and did not warrant discontinuation of therapy.